better known as Ozempic and Wegovy, following a surge in demand for the medication. A new medical study published this month suggests yes — with some key factors to keep in mind. Long-term ...

Ozempic improved walking distance in patients with diabetes and peripheral artery disease at 1 year. An exploratory analysis suggested Ozempic reduced risk for major limb events and mortality.

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly ...